Umoja Biopharma

We are thrilled to announce Scott Myers as our new board chairman. Please join us in welcoming Scott to Umoja! Full details: https://lnkd.in/g_th3kRU

Please join us at ASH in December as we share new details of our UB-VV111 (CD19) and UB-VV310 (CD20) VivoVec in vivo CAR T programs, and new science behind our off-the-shelf cell platform as well. Full details on our oral and poster presentations can be found here: https://lnkd.in/gkfwdi-i

We are excited to announce that our co-founder and CEO Andy Scharenberg has been named to the PharmaVoice 100 list! Andy's leadership has been instrumental in advancing our groundbreaking work in developing in vivo CAR T-cell therapies, with our focus now firmly on advancing that science in the clinic—all with the goal of making these life-saving treatments more effective and more accessible to patients and physicians. Read more here and view the full list: https://lnkd.in/gPms6D_W

As the 4th quarter of scientific meetings continues, please join us at SITC in November for Jeffrey Teoh's poster presentation on our CD22 in vivo CAR T products and Dillon Jarrell's poster presentation on our technology applications in other off-the-shelf products. Full details here: https://lnkd.in/gUkDBQy3

We look forward to our first presentation of VivoVec's in vivo autoimmunity applications at the upcoming ACR Convergence 2024! Please join Maura Parker in Washington D.C. as she highlights our early in vitro and in vivo data for autoimmunity in November. Full details: https://lnkd.in/g6CMgWv6

Please join us at next week's CAR-TCR Summit in Boston as Ryan Crisman, our Co-founder and CTO, presents on our foundational operations investments and joins an industry panel on the emerging promise of the in vivo space. Full details here: https://lnkd.in/gUD-x7dE

Our co-founder and CTO Ryan Crisman will be presenting at tomorrow's Wedbush Securities PacGrow Healthcare Conference on an industry panel titled "Breaking Out of Cell Therapy," covering the promising future of off-the-shelf cell therapy approaches including our own here at Umoja Biopharma. If you are attending the Wedbush conference, please join us live at 9:30am ET for the panel discussion.

We are thrilled to share that the FDA has cleared our Investigational New Drug (IND) application for UB-VV111, an in-situ generated CAR T-cell therapy for hematologic malignancies. We expect to treat our first patient by the end of year in our Phase 1 study, named INVICTA-1. UB-VV111 represents a significant advancement in off-the-shelf therapies, being the first in vivo CAR T cell therapy to be evaluated in the clinic here in the U.S. Learn more in our press release:

At Umoja, we aim to continuously create an environment where everyone can feel included and represented, and bring their full selves to our lofty goals of transforming the field of immunotherapy. During Pride Month this year, we honored and celebrated our LGBTQIA+ colleagues and allies along with their contributions to advance our science. Thank you to our YOUmoja committee and both our sites in Colorado and Washington for organizing such great events like this year's Pride celebrations! ?? ?? #PrideMonth #LoveIsLove #LifeSciences

We are honored to announce the publication of the first successful in vivo CAR T-cell non-human primate data in Blood, the flagship journal of American Society of Hematology, stemming from our pre-clinical investigations of our proprietary VivoVec? particles. Learn more about this continued validation of our platform and how our science at Umoja could be laying the groundwork for a paradigm shift in the field of CAR T-cell therapies: